Abstract:ObjectiveTo investigate the similarities and differences of FibroScan in the diagnosis of liver fibrosis in patients with different chronic liver diseases. MethodsThe clinical data of 516 patients with chronic liver diseases who visited Peking University First Hospital from October 2012 to January 2015 were collected, and according to the cause of disease, these patients were divided into chronic hepatitis B (CHB) group (305 patients), chronic hepatitis C (CHC) group (117 patients), and primary biliary cirrhosis (PBC) group (94 patients). The routine blood test results, liver function, FibroScan (FS) value, and abdominal ultrasound findings were recorded. The patients in each group were further divided into subgroups with FS value ＜7.3 kPa, 7.3 kPa ≤FS value ＜15 kPa, or FS value ≥15 kPa. The Kruskal-Wallis H test was used for comparison of continuous data and categorical data between multiple groups, and the Mann-Whitney U test was used for comparison between any two groups. The multiple linear regression was used to analyze the correlation of FS value with age, sex, body mass index (BMI), routine blood test results, liver function, and ultrasound parameters. ResultsIn the CHB group, sex, hemoglobin, aspartate aminotransferase (AST), albumin, alkaline phosphatase (ALP), total bilirubin (TBil), BMI, diameter of the portal vein, and ascites were the independent influencing factors for FS value (all P＜0.05); in the CHC group, platelet count, alanine aminotransferase (ALT), ALP, gamma-glutamyl transpeptidase (GGT), total bile acid, smoothness of liver surface, diameter of the portal vein, and ascites were the independent influencing factors for FS value (all P＜0.05); in the PBC group, TBil, total bile acid, and ascites were the independent influencing factors for FS value (all P＜0.05). Most indicators showed significant differences between CHB and CHC patients with different FS values (all P＜0.05). In the PBC group, only ALT (Z=-2.121, P=0.034), AST (Z=-3.027, P=0002), and spleen length (Z=-2.496, P=0.013) showed significant differences between the FS value ＜73 kPa subgroup and the 73 kPa ≤FS value ＜15 kPa subgroup; platelet count (Z=-2.289, P=0.022), albumin (Z=-2.185, P=0.029), TBil(Z=-2642, P=0.008), spleen thickness (Z=-3.317, P=0.001), spleen length (Z=-2.010, P=0.044), and diameter of the splenic vein (Z=-2.296, P=0.022) showed significant differences between the 7.3 kPa ≤FS value ＜15 kPa subgroup and the FS value ≥15 kPa subgroup. ConclusionDifferent factors affect the FS value in patients with different causes. Total bile acid and TBil are important influencing factors for FS value in PBC patients, while liver function greatly influences FS value in CHB and CHC patients, suggesting that the threshold values for FibroScan in the diagnosis of liver fibrosis should be set independently for different causes of disease.

Value of FibroScan in the Detection of Controlled Attenuation Parameters for Fatty Liver Disease

Controlled attenuation parameter for steatosis assessment in health checkup groups

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Controlled Attenuation Parameter by VCTE for Steatosis Assessment in Health Check Public with Reference to MRI-PDFF.

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement

The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan® CAP Values among the Taiwanese Population

A Novel Non-Invasive Index for the Prediction of Liver Fibrosis in Chronic Hepatitis B Patients with Concurrent Nonalcoholic Fatty Liver Disease

Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction

Simple surrogate equations to predict controlled attenuation parameter values for screening non-alcoholic fatty liver disease in a Chinese population

FibroScan in diagnosis of liver fibrosis in patients with different chronic liver diseases: a comparative analysis

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

The Diagnostic Value of Novel Ultrasound Attenuation Analysis in Detecting Liver Steatosis Identified by the Controlled Attenuation Parameter: a Diagnostic Accuracy Study

Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch

Accuracy of FibroScan in Analysis of Liver Fibrosis in Patients with Concomitant Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Controlled attenuation parameter (CAP): the clinical value based on MRI-PDFF in children with obesity

Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients

Effects of Changes in Photoperiod on Freezability of Ram Spermatozoa

Clinical research of fibroscan ‒ TE-CAP at noninvasive diagnosis of hepatic steatosis in children